Pepgen announces presentations at the 2025 muscular dystrophy association clinical & scientific conference

Boston--(business wire)--pepgen inc. (nasdaq: pepg), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that the company will be presenting two oral presentations as well as five posters at the 2025 muscular dystrophy association (mda) clinical & scientific conference, being held march 16-19, 2025 in dallas, tx. the oral presentations.
PEPG Ratings Summary
PEPG Quant Ranking